ClinicalTrials.gg
CompletedNCT03331627Updated Mar 25, 2020

Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL

A Phase 3 interventional study of STR001-IT and STR001-ER in Acute Hearing Loss, sponsored by Strekin AG. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by Strekin AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

a multicenter, double-blind, placebo-controlled study in patients with Sudden Sensorineural Hearing Loss (SSHL). Patients will be treated with STR001 thermogel (STR001-IT) / STR001 tablets (STR001-ER) and corresponding Placebo on top of standard of care.

02

Conditions studied

  • Acute Hearing Loss

Browse trials for

03

In context

Hearing Loss

796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

This study's enrollment of 165 is above the median of 44 across 561 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

This is the only study on the registry with Strekin AG as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥ 18
  2. Patients with a SSHL within 96 hours of its perception
  3. Sudden Sensorineural Hearing Loss including

    1. idiopathic unilateral Sudden Sensorineural Hearing Loss or
    2. acute uni- or bilateral acoustic trauma-induced Sudden Sensorineural Hearing Loss

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of Meniere's Disease
  2. Patients with a hearing threshold above 100 dB across at least 6 frequencies
  3. Patients with endolymphatic, hydrops or history of fluctuating hearing loss
  4. Patients with suspected perilymph fistula, membrane rupture, retrocochlear lesions or a barotrauma
  5. Patients with an air-bone gap of ≥ 20 dB in 3 contiguous frequencies at baseline
  6. Previous SSHL incident at the same ear
  7. Patients with acute or chronic otitis media or otitis externa.
  8. Patients with congenital hearing loss
  9. Patients with known to pioglitazone, other thiazolidindiones or any formulation component
  10. Use of thiazolidinedione (e.g. pioglitazone, rosiglitazone) in the last 6 months prior to baseline
  11. Any use of CYP450 2C8 inducers (e.g. rifampicine)
  12. Fibrates (e.g. gemfibrozil, fenofibrate) in the last 6 months prior to baseline
  13. Patients where oral administration of pioglitazone is (i.e. cardiac failure or history of cardiac failure ( stages I to IV), hepatic impairment, diabetic ketoacidosis, current bladder cancer or a history of bladder cancer, uninvestigated macroscopic haematuria
  14. Women who are breastfeeding, pregnant or plan to get pregnant during the trial duration
  15. Women of unwilling or unable to practice effective method of
  16. Participation in other clinical trials in the last month prior to baseline
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Active comparator
    STR001-IT/STR001-ER

    Drug: STR001-IT and STR001-ER

  • Active comparator
    STR001-IT/STR001-ER Placebo

    Drug: STR001-IT and STR001-ER

  • Placebo comparator
    STR001-IT placebo/STR001- ER placebo

    Drug: STR001-IT and STR001-ER

Interventions

  • DrugSTR001-IT and STR001-ER

    Drug page: Pioglitazone

    STR001-IT intrataympanic injection and STR001-ER tablet

06

What researchers measure

Primary outcomes

  1. Absolute hearing improvement after 12 weeks

    Absolute hearing improvement after 12 weeks measured with PTA using the mean value of the 3 most affected contiguous baseline frequencies (dB)

    Time frame: 12 weeks

Secondary outcomes

  1. complete hearing recovery after 12 weeks

    Percentages of patients with complete hearing recovery after 12 weeks measured with PTA using the mean value of the 3 most affected contiguous frequencies at baseline

    Time frame: 12 weeks

07

Study locations

3 sites
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, Czechia
  • Universitätsklinik Freiburg
    Freiburg, 79106, Germany
  • Universitätsspital Zürich
    Zürich, 8091, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Feb 2020, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2017
First posted
Nov 6, 2017
StartActual
Feb 24, 2018
Primary completionActual
Feb 6, 2020
CompletionActual
Feb 6, 2020
Last update
Mar 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03331627
Lead sponsor
Strekin AG
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Feb 24, 2018
Primary completion
Feb 6, 2020
Completion
Feb 6, 2020
Last update
Mar 25, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion